UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
British journal of ophthalmology, ISSN 0007-1161, 12/2014, Volume 98, Issue 12, pp. 1636 - 1641
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Prospective Studies | Enzyme-Linked Immunosorbent Assay | Intravitreal Injections | Humans | Vascular Endothelial Growth Factor A - blood | Half-Life | Biological Availability | Male | Angiogenesis Inhibitors - pharmacokinetics | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Tissue Distribution | Vitreous Body - metabolism | Wet Macular Degeneration - metabolism | Antibodies, Monoclonal, Humanized - pharmacokinetics | Receptors, Vascular Endothelial Growth Factor - pharmacokinetics | Recombinant Fusion Proteins - pharmacokinetics | Ranibizumab | Female | Aged | Research | Pharmacokinetics | Vascular endothelial growth factor | Analysis | Macular degeneration | Studies | Oncology | Diabetes | Drug dosages | Molecular weight | Index Medicus | Retina | 1506 | Clinical Science
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2006, Volume 113, Issue 3, pp. 363 - 372.e5
Biological and medical sciences | Miscellaneous | Medical sciences | Ophthalmology | Retina - drug effects | Choroidal Neovascularization - diagnosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Choroidal Neovascularization - etiology | Male | Retinal Detachment - drug therapy | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Bevacizumab | Antibodies, Monoclonal, Humanized | Choroidal Neovascularization - drug therapy | Retinal Detachment - diagnosis | Aged, 80 and over | Vitreous Body | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Fluorescein Angiography | Macular Degeneration - physiopathology | Tomography, Optical Coherence | Fovea Centralis | Macular Degeneration - complications | Vascular Endothelial Growth Factor A - immunology | Visual Acuity | Choroidal Neovascularization - physiopathology | Pigment Epithelium of Eye | Injections | Antibodies, Monoclonal - administration & dosage | Papilledema - diagnosis | Aged | Retina - pathology | Papilledema - drug therapy | Macular degeneration | Physiological aspects | Eye diseases | Angiogenesis inhibitors | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2008, Volume 115, Issue 10, pp. e47 - e54
Ophthalmology | Prospective Studies | Retinal Vein Occlusion - diagnosis | Tomography, Optical Coherence | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Visual Acuity | Retinal Vein Occlusion - complications | Antibodies, Monoclonal, Humanized | Macular Edema - etiology | Injections | Pilot Projects | Antibodies, Monoclonal - administration & dosage | Macular Edema - diagnosis | Macular Edema - drug therapy | Ranibizumab | Aged, 80 and over | Vitreous Body | Adult | Female | Aged | Fluorescein Angiography | Index Medicus
Journal Article
JAMA ophthalmology, ISSN 2168-6165, 01/2019, Volume 137, Issue 4, pp. 382 - 389
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Diabetic Retinopathy - drug therapy | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Humans | Macular Edema - pathology | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Ranibizumab - therapeutic use | Diabetic Retinopathy - pathology | Diabetic Retinopathy - physiopathology | Macular Edema - physiopathology | Macular Edema - drug therapy | Angiogenesis Inhibitors - therapeutic use | Female | Aged | Visual Acuity - physiology | Macula Lutea - pathology | Edema | Diabetic retinopathy | Retinopathy | Diabetes mellitus | Clinical trials | Patients | Acuity | Bevacizumab | Eye | Vision | Hemoglobin | Diabetes | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus | Online First | Original Investigation | Research
Journal Article
Retina (Philadelphia, Pa.), ISSN 0275-004X, 10/2017, Volume 37, Issue 10, pp. 1847 - 1858
anti-VEGF | pharmacokinetics | retinal vein occlusion | age-related macular degeneration | diabetic macular edema | Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Diabetic Retinopathy - drug therapy | Prospective Studies | Follow-Up Studies | Intravitreal Injections | Ranibizumab - pharmacokinetics | Humans | Middle Aged | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Angiogenesis Inhibitors - administration & dosage | Female | Recombinant Fusion Proteins - administration & dosage | Bevacizumab - administration & dosage | Enzyme-Linked Immunosorbent Assay | Vascular Endothelial Growth Factor A - blood | Bevacizumab - pharmacokinetics | Angiogenesis Inhibitors - pharmacokinetics | Macular Edema - blood | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Wet Macular Degeneration - diagnosis | Diabetic Retinopathy - blood | Wet Macular Degeneration - drug therapy | Recombinant Fusion Proteins - pharmacokinetics | Macular Edema - drug therapy | Wet Macular Degeneration - blood | Ranibizumab - administration & dosage | Aged | Drug therapy | Retinal diseases | Index Medicus | Original Study
Journal Article
6.
Full Text
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2006, Volume 113, Issue 10, pp. 1695 - 1705.e6
Miscellaneous | Diabetes. Impaired glucose tolerance | Retinopathies | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Ophthalmology | Endocrine pancreas. Apud cells (diseases) | Diabetic Retinopathy - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Diabetic Retinopathy - diagnosis | Angiogenesis Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Vitreous Body | Adult | Female | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Fluorescein Angiography | Iris - blood supply | Retinal Neovascularization - diagnosis | Neovascularization, Pathologic - diagnosis | Tomography, Optical Coherence | Vascular Endothelial Growth Factor A - immunology | Visual Acuity | Injections | Antibodies, Monoclonal - administration & dosage | Neovascularization, Pathologic - drug therapy | Aged | Retinal Neovascularization - drug therapy | Diabetic retinopathy | Care and treatment | Angiogenesis inhibitors | Neovascularization | Consulting services | Index Medicus
Journal Article
Retina (Philadelphia, Pa.), ISSN 0275-004X, 04/2007, Volume 27, Issue 4, pp. 419 - 425
Intravitreal | Macular edema | Branch retinal vein occlusion | Avastin | Bevacizumab | Tomography, Optical Coherence | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Visual Acuity | Retinal Vein Occlusion - complications | Antibodies, Monoclonal, Humanized | Macular Edema - etiology | Injections | Retinal Vein Occlusion - drug therapy | Macular Edema - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Vitreous Body | Adult | Female | Aged | Retrospective Studies | Fluorescein Angiography | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 06/2020, Volume 127, Issue 6, pp. 769 - 783
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Choroidal Neovascularization - diagnosis | Prospective Studies | Follow-Up Studies | Geographic Atrophy - diagnosis | Humans | Middle Aged | Geographic Atrophy - drug therapy | Geographic Atrophy - physiopathology | Male | Immunoglobulin Fab Fragments - therapeutic use | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Vision Disorders - physiopathology | Choroidal Neovascularization - drug therapy | Aged, 80 and over | Female | Visual Acuity - physiology | Fluorescein Angiography | Macular Degeneration - physiopathology | Macular Degeneration - complications | Geographic Atrophy - etiology | Choroidal Neovascularization - physiopathology | Disease Progression | Aged | Choroidal Neovascularization - complications | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 06/2020, Volume 127, Issue 6, pp. 769 - 783
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2015, Volume 122, Issue 9, pp. 1846 - 1853.e5
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Geographic Atrophy - physiopathology | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Retinal Pigment Epithelium | Wet Macular Degeneration - drug therapy | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Retina - pathology | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2015, Volume 122, Issue 2, pp. 391 - 398.e5
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Choroidal Neovascularization - diagnosis | Prospective Studies | Follow-Up Studies | Intravitreal Injections | Humans | Male | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Retinal Hemorrhage - diagnosis | Antibodies, Monoclonal, Humanized - administration & dosage | Choroidal Neovascularization - drug therapy | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Retinal Hemorrhage - physiopathology | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Treatment Outcome | Choroidal Neovascularization - physiopathology | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Aged | Retinal Hemorrhage - drug therapy | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Photodiagnosis and photodynamic therapy, ISSN 1572-1000, 2015, Volume 12, Issue 2, pp. 314 - 316
Hematology, Oncology and Palliative Medicine | Internal Medicine | Photocoagulation | Retinal detachment | Retinal tear | Laser | Life Sciences & Biomedicine | Oncology | Science & Technology | Retinal Detachment - etiology | Female | Retinal Perforations - etiology | Light Coagulation - adverse effects | Humans | Middle Aged | Laser coagulation |